Related Concept Videos
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Mitochondrial dysfunction in lung ageing and disease.
European respiratory review : an official journal of the European Respiratory Society·2020
Same author
COPD 2020: new directions needed.
American journal of physiology. Lung cellular and molecular physiology·2020
Same author
Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.
The Lancet. Respiratory medicine·2020
Related Experiment Video
Updated: Jul 18, 2026
08:17
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
Advances in chronic obstructive pulmonary disease.
1Thoracic Medicine, the National Heart and Lung Institute.
Transactions of the Medical Society of London
|December 23, 2006
Summary
Chronic Obstructive Pulmonary Disease (COPD) treatments are limited, with no cure preventing disease progression. New therapies targeting nicotine addiction and inflammation are needed to improve lung function and patient outcomes.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of global morbidity and mortality with increasing prevalence.
- Current treatments offer limited efficacy in preventing the progressive decline of lung function characteristic of COPD.
Purpose of the Study:
- To review current COPD management strategies and highlight the unmet need for more effective therapies.
- To discuss emerging drug classes in development for COPD treatment.
Main Methods:
- Literature review of current COPD therapies, including bronchodilators, inhaled corticosteroids, and oxygen therapy.
- Examination of smoking cessation aids and their effectiveness.
- Overview of novel therapeutic agents under investigation for COPD.
Main Results:
- Smoking cessation is the only intervention proven to reduce lung function decline, with bupropion being the most effective aid.
- Inhaled anticholinergics and long-acting beta2-agonists are effective bronchodilators for symptom relief and reducing hyperinflation.
- Inhaled corticosteroids show limited efficacy, but combination inhalers demonstrate improved effects; long-term oxygen therapy is crucial for advanced disease.
Conclusions:
- There is a critical need for novel therapeutic classes to address the progressive nature of COPD.
- Emerging treatments, including interleukin-8 antagonists, phosphodiesterase-4 inhibitors, protease inhibitors, and antioxidants, show promise for future COPD management.